Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD21: BrECADD vs BEACOPP in Advanced Hodgkin Lymphoma
NCT02661503Phase 3Active, not recruiting
- Sponsor
- University of Cologne
- Start
- Jul 2016
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Started Jul 2016; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02661503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661503.